Tendinosis News and Research

RSS

Tendinosis, sometimes called chronic tendinitis, tendinosus, chronic tendinopathy or chronic tendon injury, is damage to a tendon at a cellular level (the suffix "osis" implies a pathology of chronic degeneration without inflammation).

Super-resolution imaging reveals how disease causes cells to reorder their DNA incorrectly

Imagine you're trying to do a job and all of the information you need to do it is in a few books at the library.

22 Aug 2022

Researchers explore better treatments for irritated tendons

When tendons get irritated it can lead to a serious condition called tendinosis -- a common class of sports and workplace injuries -- which is also common in older individuals. It can take many weeks of rest for tendon irritation to heal, with no treatments, save short-term steroid injections and surgery, followed by more rest.

3 Apr 2019

RepliCel Life Sciences announces final design specifications for next-generation dermal injector

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company, is pleased to announce that the final design specifications of its next-generation dermal injector (RCI-02) have been locked. Prototypes for industrial and regulatory testing will now be built to prepare for an application for CE mark clearance to market the injector in Europe in 2016.

29 Jul 2015

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial.

21 Jul 2015

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.

30 Jun 2015

RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today an upcoming poster presentation at the International Society for Cellular Therapy on RepliCel's autologous cell treatment for chronic Achilles tendinosis currently in a Phase 1/2 clinical trial.

21 May 2015

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.

23 Feb 2015

PRP therapy improves functionality of tendons in athletes with degenerative disease

Ultrasound-guided delivery of platelet-rich plasma improves functionality and reduces recovery time in athletes with degenerative disease in their tendons, according to a study being presented today at the annual meeting of the Radiological Society of North America.

2 Dec 2013

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Researchers at Hospital for Special Surgery have been awarded a $100,000 grant from the National Football League (NFL) Charities to research the use of platelet-rich plasma (PRP) and stem cells as treatments for tendon injury and degeneration. For years, PRP has been used to improve healing in various sports injuries, but there is little evidence of its efficacy.

12 Sep 2012

BioMimetic Therapeutics reports net loss of $7.7M for second-quarter 2010

BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.

6 Aug 2010

ACOEM publishes new medical treatment guidelines for hip and groin disorders

The American College of Occupational and Environmental Medicine today published new medical treatment guidelines for providing care to workers with injuries and disorders of the hip and groin. The new guidelines, which represent the latest chapter in ACOEM's comprehensive publication Occupational Medicine Practice Guidelines, are available on line now via ACOEM's APG-I web application; a print version will be available in the fall of 2010, when the Third Edition hard-copy of Occupational Medicine Practice Guidelines is published.

26 May 2010

Alternative non-surgical method to treat chronic tendinosis

Researchers have found an alternative, "non-surgical" method to treat chronic tendinosis (tendinitis) of the Achilles tendon that fails conservative treatment, according to a study performed at the Feinberg School of Medicine, Northwestern University in Chicago, IL.

23 Apr 2009

Injected dextrose solution helps ease chronic Achilles tendon pain

Patients with chronic tendinosis of the Achilles tendon can experience a reduction in pain when injected with a small amount of a dextrose solution, according to a recent study conducted by researchers at St. Paul's Hospital in Vancouver, BC.

29 Oct 2007